The effect of lactulose supplementation on fecal microflora of patients with chronic kidney disease; a randomized clinical trial.
BACKGROUND
Lactulose is a prebiotic with bifidogenic and urea reduction effects. It can improve Bifidobacteria and Lactobacilli counts in healthy humans and it may possibly have similar effects in chronic kidney disease (CKD) patients.


OBJECTIVE
To investigate the effect of lactulose on fecal microflora of patients with CKD.


METHODS
Thirty-two patients with stages 3 and 4 of CKD (43.8% male with mean age of 58.09±12.75 years) were randomly assigned to intervention (n=16) and control (n=16) groups. Patients in intervention group received 30 mm lactulose syrup three times a day for an 8-week period. Control group received placebo 30 mm three times a day. A fecal sample was obtained from all patients at the beginning and at the end of the study and Bifidobacteria and Lactobacilli was counted.


RESULTS
Creatinine (Cr) significantly decreased in intervention group (3.90±1.43 to 3.60±1.44, P=0.003) and increased in control group (3.87±2.08 to 4.11±1.99, P=0.03). Although Bifidobacterial and Lactobacilli counts were similar before intervention, they were significantly higher at the end of the study in lactulose group (P=0.01 and P=0.04, respectively). Lactulose led to significant increase in fecal Bifidobacterial counts (3.61±0.54 to 4.90±0.96, P<0.001) and Lactobacilli counts (2.79±1.00 to 3.87±1.13, P<0.001), while the change in placebo group was not significant.


CONCLUSIONS
Lactulose administration will increase Bifidobacteria and Lactobacillus counts in patients with CKD.
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Hamid
H
Tayebi-Khosroshahi
Medical Education Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Afshin
A
Habibzadeh
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Bahram
B
Niknafs
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Reza
R
Ghotaslou
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Fatemeh
F
Yeganeh Sefidan
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Morteza
M
Ghojazadeh
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Majid
M
Moghaddaszadeh
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Sahar
S
Parkhide
Bifidobacteria; Chronic kidney disease; Fecal microflora; Lactobacilli; Lactulose
Eur J Clin Nutr. 2004 Mar;58(3):462-6
14985684
Nutr Hosp. 2014 Mar 01;29(3):582-90
24559003
Toxins (Basel). 2013 Nov 07;5(11):2042-57
24212182
Iran J Kidney Dis. 2014 Sep;8(5):377-81
25194404
Br J Nutr. 2001 Sep;86(3):341-8
11570986
J Surg Oncol. 1971;3(2):163-8
5094276
J Vet Med A Physiol Pathol Clin Med. 2005 Aug;52(6):263-7
16050905
Arch Anim Nutr. 2006 Jun;60(3):191-204
16736854
J Am Coll Nutr. 2006 Dec;25(6):541-9
17229902
Kidney Int. 2013 Feb;83(2):308-15
22992469
Aliment Pharmacol Ther. 2008 Mar 15;27(6):504-13
18081736
BMJ. 2001 Oct 20;323(7318):936
11668146
Scand J Gastroenterol Suppl. 1997;222:83-7
9145455
J Am Soc Nephrol. 2011 Sep;22(9):1769-76
21784895
Ter Arkh. 1993;65(6):41-3
8378848
Gut. 1987 Mar;28(3):255-9
3570029
Adv Biochem Eng Biotechnol. 2008;111:1-66
18461293
Appl Environ Microbiol. 2006 Sep;72(9):5990-7
16957220
Aliment Pharmacol Ther. 2004 Apr 15;19(8):889-99
15080850
Am J Vet Res. 2004 Mar;65(3):338-43
15027683
Gut. 2004 Nov;53(11):1590-4
15479678
Ter Arkh. 2008;80(2):52-7
18372597
Br J Nutr. 2010 Aug;104 Suppl 2:S1-63
20920376
Am J Clin Nutr. 2004 Dec;80(6):1658-64
15585783
Scand J Gastroenterol Suppl. 1997;222:100-1
9145459
Kidney Int Suppl. 2009 Dec;(114):S12-9
19946322
Scand J Gastroenterol Suppl. 1997;222:62-4
9145450
J Nutr. 1999 Jul;129(7 Suppl):1478S-82S
10395625
Gastroenterology. 1995 Apr;108(4):975-82
7698613
Acta Biochim Pol. 2012;59(2):271-4
22540114
Kidney Int. 2006 Mar;69(6):1081-7
16421516
Mol Nutr Food Res. 2013 May;57(5):824-32
23450842
Nutrients. 2013 Apr 22;5(4):1417-35
23609775
Gut. 2004 Nov;53(11):1610-6
15479681